Refine your search
Collections
Co-Authors
Year
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z All
Mahanti, B.
- Phase-3 Studies of Welchol on Anti-Diabetic Activity
Abstract Views :213 |
PDF Views:2
Authors
Affiliations
1 Bharat Technology, Banitabla, Howrah, W.B, IN
2 Calcutta Institute of Pharmaceutical Technology and AHS, Uluberia, Howrah, IN
1 Bharat Technology, Banitabla, Howrah, W.B, IN
2 Calcutta Institute of Pharmaceutical Technology and AHS, Uluberia, Howrah, IN
Source
Research Journal of Pharmacology and Pharmacodynamics, Vol 2, No 3 (2010), Pagination: 211-214Abstract
Diabetes is a condition primarily defined by the level of hyperglycaemia giving rise to risk of macro and micro vascular complication and diminished quality of life. Roman physician Areataeus was introduced the name diabetes in 1st century A.D. Diabetes treatment include a number of drugs either can be used alone or in combination. The present articles concentrate on the phase-3 studies of Welchol as an adjunct to Metformin in type-ll diabetes who are not responding to other combination of anti-diabetic drugs.Keywords
Diabetes, Hyperglycaemia, Complications, Welchol.
References
- Finkel.R, Clark,M,A; Cubeddu,L.X; Hervey,R,A; Champe,P.C; Li ppincott's Illustrated review: Pharmacology 4th edition. New Delhi: Wolter Kluwer/Lippincott Williams and Wilkins, pp.285-297.
- Harold E. Bays, MD; Ronald B. Goldberg, MD; Kenneth E. Truitt, MD; Michael R. Jones; Colesevelam Hydrochloride Therapy in Patients With Type 2 Diabetes Mellitus Treated With Metformin. Arch Intern Med.2008; 168(18):pp.1975-1983.
- Goldberg R.B; Fonseca V.A; Truitt K.E; Jones M.R ;Archives of internal medicine: efficacy and safety of Colesevelam in patients with type-2 diabetes mellitus and inadequate glycemic control receiving insulin based therapy, Lipid Disorder Clinic, Division of endocrinology, Diabetes and Metabolism, and Diabetes Research Institute, University of Miami Miller School of Medicine, Miami, FL;2008; 33136, USA.
- Satoshkar R.S, Bhandarkar Sd, Nirmala N.R: Pharmacology and pharmacotherapeutics,12th ed;2007;pp.869-900.
- RXLIST-The interdrug index,july,2008, copyright(c) 2008, First Data Bank.,Inc.
- Staels.B, Kuipers.F; Bile acid sequestrants and the treatment of type-2 diabetes mellitus. Drugs; 2007; 67 (10); pp.1383-92.
- Welchol (Colesevelam hydrochloride) prescribing information. Parsippany, NJ: Daiichi Sankyo, Inc; 2008.
- Denkins DJ, et al. Effect of a low glycemic index or a high cereal fiber diet on type 2 diabetes: A randomized trial. Journal of the American Medical Association. 2008; pp.300:2742
- Sigal RJ, et al. Effects of aerobic training, resistance training, or both on glycemic control in type 2 diabetes. Annals of Internal Medicine. 2007; pp.147:357.
- Zema F.J; Colesevelam hydrochloride and ezetimibe combination therapy provides effective lipid lowering in difficult to treat patients with hypercholesterolemia; American journal of Therapeutics;2005; 12(4);pp.306-310.
- Sembulingam K ,Sembulingam P, et.al ; Essentials of medical physiology, 4th edn. New Delhi 1999, 4th edn: pp.236-253.
- Davis S.N, Granner D.K; Insulin, oral hypoglycemic agent, and the pharmacology of endocrine pancreas. In Hardman, J.G Limbird, J.E Goodman and Gilmans: The pharmacology basis of therapeutic, McGraw Hill, New Delhi. 2001; 10th ed: pp.989-990 and 1679-1710.
- Zieve F.J, Kalin M.F; Schwartz S.L; Jones M.R; Bailey W.L; Results of the glucose lowering effect of Welchol study (GLOWS);A randomized, double-bind placebo controlled pilot study evaluating the effect of Colesevelam hydrochloride on glycemic control in subjects with type-2 diabetes. Clinical therapeutics; 2007;29(1), pp.74-83.
- Brufau G, et al. Altered bile salt metabolism in type 2 diabetes mellitus (T2DM). Abstract presented at the ADA 68th Scientific Sessions; San Francisco, CA (June 2008).
- Beysen C et al. Colesevelam HCl Improves Glucose Metabolism and Increases Glucagon-like Peptide 1 and Glucose-dependent Insulinotropic Polypeptide Concentrations in Type 2 Diabetes. Abstract presented at the 49th Annual Meeting of the European Association for the Study of Diabetes, Vienna, Austria (September 29 – October 2, 2009).